Ranbaxy Laboratories’ arm launches authorized generic of Pioglitazone in the US

Ranbaxy Laboratories’ (RLL) wholly owned subsidiary - Ranbaxy Pharmaceuticals Inc., has launched authorized generic pioglitazone hydrochloride tablets in the US market, under an agreement with Takeda Pharmaceuticals U.S.A., Inc.

Pioglitazone hydrochloride tablets is an oral antidiabetic agent that acts primarily by decreasing insulin resistance, presently distributed by Takeda Pharmaceuticals America, Inc. under the brand name Actos. The product is indicated for patients as an adjunct to diet and exercise to improve glycemic controls in adults with type 2 diabetes mellitus. Actos generated total annualized sales of $2.7 billion in the US (IMS - MAT June 2012).

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.